Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Lyophilized Drugs Focus of Delivery Device Suppliers

Lyophilized Drugs a Focus of Delivery Device Suppliers as Point-of-Use Reconstitution and Self-Administration Converge

Greystone Research Associates Finds High-Growth Markets Hinge on the Ability of Users to Safely and Reliably Reconsitute Solid Injectable Formulations

(Amherst, NH) – The ability of a growing number of New Chemical Entities (NCEs) to have commercial value as therapeutic drugs rests in the capability of developers to create formulations that render them stable at ambient temperatures. Once created, end users – caregivers and patients – must have a way to reconstitute them prior to administration. These requirements have fostered two industry segments designed to address the growing need for creating powder forms of injectables, and for developing devices that allow them to be reconstituted simply and without introducing medication errors.

Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biologicals. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they are ready for use. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render it unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent.

The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. Innovation and growth in drug reconstitution systems is being driven by two significant markets. The first is the self-administration of injectable biologicals. Several innovative injection devices package the drug powder and diluent in separate chambers within a single device. This allows the patient to reconstitute medication without the need for handling, measuring, and/or separate mixing steps, and enables biological drug developers to create lyophilized drug products indicated for chronic conditions that can be self-administered safety and reliably.

Another important trend is aimed at improving the safety of cytotoxic drug reconstitution. The focus here is on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Several companies are responding to this unmet need by commercializing systems for closed transfer of these drugs.

Detailed analysis of the devices and systems for reconstituting drugs at the point-of-care is included in a new and comprehensive report. The report – Point-of-Delivery Drug Reconstitution Systems - includes assessments of devices and therapeutic market segments, analysis of market factors, and profiles of market participants.

More information is available at

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Source: Greystone Research Associates

© Scoop Media

Business Headlines | Sci-Tech Headlines


Banks: Westpac Keeps Core Government Transactions Contract

The local arm of Westpac Banking Corp has kept its contract with the New Zealand government to provide core transactions, but will have to share peripheral services with its rivals. More>>


Science Investment Plan: Universities Welcome Statement

Universities New Zealand has welcomed the National Statement of Science Investment released by the Government today... this is a critical document as it sets out the Government’s ten-year strategic direction that will guide future investment in New Zealand’s science system. More>>


Scouring: Cavalier Merger Would Extract 'Monopoly Rents' - Godfrey Hirst

A merger of Cavalier Wool Holdings and New Zealand Wool Services International's two wool scouring operations would create a monopoly, says carpet maker Godfrey Hirst. The Commerce Commission on Friday released its second draft determination on the merger, maintaining its view that the public benefits would outweigh the loss of competition. More>>


Scoop Review Of Books: She Means Business

As Foreman says in her conclusion, this is a business book. It opens with a brief biographical section followed by a collection of interesting tips for entrepreneurs... More>>


Hourly Wage Gap Grows: Gender Pay Gap Still Fixed At Fourteen Percent

“The totally unchanged pay gap is a slap in the face for women, families and the economy,” says Coalition spokesperson, Angela McLeod. Even worse, Māori and Pacific women face an outrageous pay gap of 28% and 33% when compared with the pay packets of Pākehā men. More>>


Housing: English On Housing Affordability And The Economy

"Long lead times in the planning process tend to drive prices higher in the upswing of the housing cycle. And those lead times increase the risk that eight years later, when additional supply arrives, the demand shock that spurred the additional supply has reversed. The resulting excess supply could produce a price crash..." More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news